Intermittent (versus continuous) androgen deprivation therapy (ADT) seems to be associated with an increase in the incidence of ischaemic and thrombotic events, according to a new study. Hershman et al. linked Medicare claims data with data from a multicentre trial comparing intermittent with continuous ADT. They found that the 10-year cumulative incidence of ischaemic and thrombotic events was 24% in the continuous ADT group and 33% in the intermittent ADT group. No differences were seen between groups in bone, endocrine or cognitive events.
References
Hershman, D. L. et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. http://dx.doi.org/10.1001/jamaoncol.2015.4655 (2015)
Rights and permissions
About this article
Cite this article
Kelsey, R. Adverse events associated with intermittent ADT. Nat Rev Urol 13, 64 (2016). https://doi.org/10.1038/nrurol.2016.8
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.8